Symbols

Symbols

EHAB

EHAB

Enhabit Reports Q3 Revenue Below Expectations, Focuses on Financial Stability

Enhabit Reports Q3 Earnings Beat, Updates FY25 Outlook

Wednesday Nov 05, 2025

Enhabit reports Q3 2025: $263.6mln rev, $11.1mln net income, $27mln adj. EBITDA.

Sunday Oct 26, 2025

Curreen Capital Partners Q3 2025 Letter: Enhabit Sale, New Investments in Kontoor and More

Wednesday Oct 01, 2025

Enhabit Insiders Buy Shares Amid Positive Market Trends

Monday Sep 29, 2025

Enhabit Home Health & Hospice Q3 2025 Financial Performance Highlights

Monday Aug 11, 2025

Enhabit CFO Solomon Ryan Buys 10,000 Shares at $7.64/Share.

Q2 Earnings Analysis: Chemed (NYSE:CHE) Leads Senior Health, Home Health & Hospice Stocks

Sunday Aug 10, 2025

UBS Lowers Price Target for Enhabit (EHAB) to $8.50, Maintains Neutral Rating.

UBS Lowers Enhabit Price Target to $8.50 from $10, Maintains Neutral Rating

Friday Aug 08, 2025

UBS Keeps Enhabit Neutral Rating, PT Down to $8.5 from $10

Thursday Aug 07, 2025

Enhabit, Inc. shares rise 5.76% premarket after reporting strong Q2 earnings and raising annual guidance.

Enhabit CEO Transition Plan Announced, Jacobsmeyer to Step Down by July 31, 2026

Enhabit CEO Transition Plan Announced: Barb Jacobsmeyer to Step Down in July 2026

Enhabit CEO Jacobsmeyer to Step Down in July 2026

Wednesday Aug 06, 2025

Enhabit CEO Barb Jacobsmeyer to step down in July 2026.

Enhabit Q2 revenue up 6.6% YoY, increases FY23 guidance.

Wednesday Jul 23, 2025

Smith+Nephew to Announce Q2 and H1 2025 Results on August 5

Tuesday Jul 22, 2025

Smith & Nephew: KDJ Golden Cross, Bullish Marubozu on 15min Chart

Tuesday Jul 08, 2025

Enzo Health Forms Advisory Board to Drive Home-Based Care Innovation